Alex A.C.
Value/GARP Investor, Semiconductor & Financial Analysis, Electronics MEng
Aehr Test Systems is key to AI manufacturing and can even be a bottleneck, but at almost 20x revenue through 2028 at the current price, it is stratospherically priced. The risk is giant if something goes wrong for the company or for the AI ramp, and even a slowdown could be deadly at such high valuations. Tech moats are not the same as financial moats. x.comÂ
Aehr Test Systems' addressable market looks tiny compared with 200 other AI companies, making it unattractive. x.comÂ
Aehr Test Systems' very lumpy machine sales typically make for a poor business model. x.comÂ
Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com x.comÂ
Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.comÂ
Aehr Test Systems is a case of narrative running ahead of the numbers. The bull case is reasonable: a young company with a strong position in silicon carbide burn-in, genuine hyperscaler interest in AI chip burn-in and room to expand into memory and logic. But the latest quarter showed revenue down 43% year over year, with no meaningful order conversion from the AI opportunities yet. Until revenue improves and orders come through more clearly, the story stays ahead of the fundamentals. x.comÂ
Aehr Test Systems' selloff reflects confusion, not fundamentals: traders dumped the stock after finance sites wrongly listed its earnings for October 6, while a strong order announcement got ignored. Its lead hyperscaler test customer, which already uses Sonoma to test one AI processor in high-volume production, ordered more equipment for a second, newer processor expected to ramp in 2027. x.comÂ
Aehr Test Systems' bull case looks overstated on a detailed financial model, summarized in a table for investors meeting CEO Gayn at the William Blair conference. x.comÂ
Financing risk makes AI-linked growth stocks unattractive to add here. Much of the money reaching suppliers such as Nvidia and Micron is financed, so harder funding would limit spending on chips, compute and memory. The buildout is not over, but stock prices could remain suppressed until it slows. A significant drawdown would make adding appealing; for many high-beta names with weak fundamentals and balance sheets, the highs look to be in. x.comÂ
Aehr Test Systems had a great quarterly call, and the stock now sits at a key pivot. x.comÂ
AI-exposed semiconductors face near-term demand risk as Anthropic's revenue growth slows. Monthly additions fell from $10B to ~$2-3B, though October may improve and one-off headwinds contributed. The AI selloff is not irrational amid rates, debt, politics and supply-chain risks. Despite long-term optimism, a short-term bull case needs an Anthropic IPO or OpenAI fundraise, calmer rates and debt funding, blowout cloud earnings with EPS upgrades, and new applications reviving token monetization. … Show more
